KALA — KALA BIO Income Statement
0.000.00%
- $9.20m
- $5.55m
Annual income statement for KALA BIO, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 6.36 | 11.2 | 3.89 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 3.19 | 7.14 | 1.33 | 0 | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 103 | 146 | 41.2 | 39.7 | 41 |
| Operating Profit | -96.2 | -134 | -37.3 | -39.7 | -41 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -104 | -143 | -44.8 | -42.2 | -38.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -104 | -143 | -44.8 | -42.2 | -38.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -104 | -143 | -44.8 | -42.2 | -38.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -104 | -143 | -44.8 | -42.2 | -38.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -99.6 | -106 | -58.7 | -17.4 | -10.1 |